StockData
AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Atea Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.39+0.07 (+1.62%)

Close on Oct 19, 2026

Market cap
$351.42M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 11, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 12, 2026After market close–––
Q1 FY2026
Ended Mar 31, 2026
May 12, 2026After market close–––
Q4 FY2025
Ended Dec 31, 2025
Mar 5, 2026After market close–$-0.57–
Q3 FY2025
Ended Sep 30, 2025
Nov 12, 2025After market close–$-0.53–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025After market close–$-0.44–
Q1 FY2025
Ended Mar 31, 2025
May 12, 2025After market close–$-0.40–
Q4 FY2024
Ended Dec 31, 2024
Mar 6, 2025After market close–$-0.40–
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024After market close–––
Q2 FY2024
Ended Jun 30, 2024
Aug 7, 2024After market close–$-0.48–
Q1 FY2024
Ended Mar 31, 2024
May 14, 2024After market close–$-0.75–
Q4 FY2023
Ended Dec 31, 2023
Feb 28, 2024After market close–$-0.47–

Press releases

Announcements Atea Pharmaceuticals filed with the SEC